دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Exercise-Induced Ventricular Ectopy and Cardiovascular Mortality in Asymptomatic Individuals
Marwan M.RefaatMDab?CharbelGhariosMDac?M. VinayagaMoorthyPhDdFarahAbdulhaiMDaRoger S.BlumenthalMDeMiran A.JaffaPhDf†SamiaMoraMD, MHSd†
doi : 10.1016/j.jacc.2021.09.1366
Volume 78, Issue 23, 7 December 2021, Pages 2267-2277
The prognosis of exercise-induced premature ventricular contractions (PVCs) in asymptomatic individuals is unclear.
Premature Ventricular Complexes During Exercise in Asymptomatic Adults: Do They Deserve a Closer Look??
Sandeep A.SahaMD, MS
doi : 10.1016/j.jacc.2021.09.1365
Volume 78, Issue 23, 7 December 2021, Pages 2278-2280
Preeclampsia Predicts Risk of Hospitalization for Heart Failure With Preserved Ejection Fraction
DominiqueWilliamsMDaMolly J.StoutMD, MSCIbJoshua I.RosenbloomMD, MPHcMargaret A.OlsenPhD, MPHdKaren E.Joynt MaddoxMD, MPHaElenaDeychMSaVictor G.Davila-RomanMDaKathryn J.LindleyMDac
doi : 10.1016/j.jacc.2021.09.1360
Volume 78, Issue 23, 7 December 2021, Pages 2281-2290
Preeclampsia is associated with increased risk of future heart failure (HF), but the relationship between preeclampsia and HF subtypes are not well-established.
Understanding Heart Failure in Women With Preeclampsia: A Call for Prevention?
Michael C.HonigbergMD, MPP
doi : 10.1016/j.jacc.2021.09.1361
Volume 78, Issue 23, 7 December 2021, Pages 2291-2293
Evolution of Late Right Heart Failure With Left Ventricular Assist Devices and Association With Outcomes
J. EduardoRameMDabFrancis D.PaganiMD, PhDcMichael S.KiernanMD, MSdGuilherme H.OliveiraMDeEdo Y.BiratiMDaPavanAtluriMDfAnnGaffeyMDfE. WilsonGrandinMD, MPH, MDgSusan L.MyersBBAhCraigCollumMPHhRobert L.KormosMDijJames K.KirklinMDhJeffrey J.TeutebergMDk
doi : 10.1016/j.jacc.2021.09.1362
Volume 78, Issue 23, 7 December 2021, Pages 2294-2308
A revised definition of right heart failure (RHF) for the Society of Thoracic Surgeons Intermacs database of left ventricular assist devices (LVADs) was introduced in June 2014.
The Other Ventricle With Left Ventricular Assist Devices?
Lynne WarnerStevensonMDaJordan R.H.HoffmanMDbJonathan N.MenachemMDa
doi : 10.1016/j.jacc.2021.09.1364
Volume 78, Issue 23, 7 December 2021, Pages 2309-2311
Abnormal Extracardiac Development in Fetuses With Congenital Heart Disease
Gregor O.DovjakMD, PhDaTimZalewskibElisabethSeidl-MlczochMDcPatricia A.UlmdVanessaBerger-KulemannMDaMichaelWeberPhDeDanielaPrayerMDaGregor J.KasprianMD, MBAaBarbaraUlmMDb
doi : 10.1016/j.jacc.2021.09.1358
Volume 78, Issue 23, 7 December 2021, Pages 2312-2322
Knowledge about extracardiac anomalies (ECA) in fetal congenital heart disease (CHD) can improve our understanding of the developmental origins of various outcomes in these infants. The prevalence and spectrum of ECA, including structural brain anomalies (SBA), on magnetic resonance imaging (MRI) in fetuses with different types of CHD and at different gestational ages, is unknown.
Extracardiac Pathology in Fetal Heart Disease: What You See Is Not Always What You Get?
Lisa K.HornbergerMDAngelaMcBrienMB, BCh, MD
doi : 10.1016/j.jacc.2021.09.1359
Volume 78, Issue 23, 7 December 2021, Pages 2323-2325
Transcatheter Mitral Valve Therapy in the United States: A Report From the STS-ACC TVT Registry
MichaelMackMDaJohn D.CarrollMDbVinodThouraniMDcSreekanthVemulapalliMDdeJohnSquiersMDaPratikManandharPhDdG. MichaelDeebMDfWayneBatchelorMDgHoward C.HerrmannMDhDavid J.CohenMD, MScijGeorgeHanzelMDkThomasGleasonMDlAjayKirtaneMDimNimeshDesaiMDnKimGuiboneDNP, ACNP-BCoKarenHardyRHIApJoanMichaelsRNqJ. MichaelDiMaioMDaBarbaraChristensenRNqSusanFitzgeraldRN, MSqCaroleKrohnRNrRalph G.BrindisMD, MPHsFredMasoudiMD, MSPHtJosephBavariaMDn
doi : 10.1016/j.jacc.2021.07.058
Volume 78, Issue 23, 7 December 2021, Pages 2326-2353
Data for nearly all patients undergoing transcatheter edge-to-edge repair (TEER) and transcatheter mitral valve replacement (TMVR) with an approved device in the United States is captured in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. All data submitted for TEER or TMVR between 2014 and March 31, 2020, are reported. A total of 37,475 patients underwent a mitral transcatheter procedure, including 33,878 TEER and 3,597 TMVR. Annual procedure volumes for TEER have increased from 1,152 per year in 2014 to 10,460 per year in 2019 at 403 sites and for TMVR from 84 per year to 1,120 per year at 301 centers. Mortality rates have decreased for TEER at 30 days (5.6%-4.1%) and 1 year (27.4%-22.0%). Early off-label use data on TMVR in mitral valve-in-valve therapy led to approval by the U.S. Food and Drug Administration in 2017, and the 2019 30-day mortality rate was 3.9%. Overall improvements in outcomes over the last 6 years are apparent. (STS/ACC TVT Registry Mitral Module; NCT02245763)
Evaluating Medical Therapy for Calcific Aortic Stenosis: JACC State-of-the-Art Review
Brian R.LindmanMD, MScaDevrajSukulMD, MSbMarc R.DweckMDcMahesh V.MadhavanMDdBenoit J.ArsenaultPhDeMeganCoylewrightMDfW. DavidMerrymanPhDgDavid E.NewbyMDcJohnLewisMAhFrank E.HarrellJr.PhDiMichael J.MackMDjMartin B.LeonMDdCatherine M.OttoMDkPhilippePibarotDVM, PhDe
doi : 10.1016/j.jacc.2021.09.1367
Volume 78, Issue 23, 7 December 2021, Pages 2354-2376
Despite numerous promising therapeutic targets, there are no proven medical treatments for calcific aortic stenosis (AS). Multiple stakeholders need to come together and several scientific, operational, and trial design challenges must be addressed to capitalize on the recent and emerging mechanistic insights into this prevalent heart valve disease. This review briefly discusses the pathobiology and most promising pharmacologic targets, screening, diagnosis and progression of AS, identification of subgroups that should be targeted in clinical trials, and the need to elicit the patient voice earlier rather than later in clinical trial design and implementation. Potential trial end points and tools for assessment and approaches to implementation and design of clinical trials are reviewed. The efficiencies and advantages offered by a clinical trial network and platform trial approach are highlighted. The objective is to provide practical guidance that will facilitate a series of trials to identify effective medical therapies for AS resulting in expansion of therapeutic options to complement mechanical solutions for late-stage disease.
Aligning Care and Payment for Chronic Cardiovascular Conditions
Paul N.CasaleMD, MPHabcChristinePerezJDdEileen P.HaganMSN, RNdRachel A.RoilandPhD, RNeRobert S.SaundersPhDe
doi : 10.1016/j.jacc.2021.09.1368
Volume 78, Issue 23, 7 December 2021, Pages 2377-2381
Weaving Antiracism Practice and Equity Into the Fabric of Cardiovascular Fellowship: A New Training Paradigm
Lauren A.EberlyMD, MPHabcdHowardJulienMD, MPH, MLabcSrinathAdusumalliMD, MSHP, MBMIabcd
doi : 10.1016/j.jacc.2021.07.063
Volume 78, Issue 23, 7 December 2021, Pages 2382-2386
RESPONSE: Coronary Anatomy, Hemodynamics, and Racism: The New Cardiology Training Curriculum?
QuinnCapersIVMD
doi : 10.1016/j.jacc.2021.07.064
Volume 78, Issue 23, 7 December 2021, Pages 2385-2386
What Is of Recent Interest in Cardiac Imaging?: Insights From the JACC Family of Journals
Leslee J.ShawPhD(Executive Editor, JACC: Cardiovascular Imaging)Y.ChandrashekharMD(Editor-in-Chief, JACC: Cardiovascular Imaging)JACC: Cardiovascular Imaging Editors
doi : 10.1016/j.jacc.2021.10.029
Volume 78, Issue 23, 7 December 2021, Pages 2387-2391
Could High-Sensitivity Cardiac Troponin Testing Rule Out Acute Myocardial Infarction in the Prehospital Setting?
Jamie G.CooperMBChBJamesFergusonMBChBLorna A.DonaldsonKim M.M.BlackJudith L.HorrillMScElaine M.DavidsonMSc, PhDNeil W.ScottMSc, PhDTakeshiFujisawaPhDAndrew R.ChapmanMD, PhDNicholas L.MillsMD, PhD
doi : 10.1016/j.jacc.2021.10.004
Volume 78, Issue 23, 7 December 2021, Pages 2392-2394
Reconsider the MitraClip for High-Risk Patients
XuanJiangMD, PhDJinduoLiuMD, PhDTianxiangGuMD, PhD
doi : 10.1016/j.jacc.2021.07.062
Volume 78, Issue 23, 7 December 2021, Page e293
Reply: Reconsider the MitraClip for High-Risk Patients
JoannaChikweMDPatrickO’GaraMDAnnetineGelijnsPhD
doi : 10.1016/j.jacc.2021.10.002
Volume 78, Issue 23, 7 December 2021, Page e295
Does Gestational Hypertension Contribute to Myocardial Fibrosis and Diastolic Dysfunction in Adult Offspring?
David W.J.ArmstrongMD, PhDM. YatTsePhDStephen C.PangPhD
doi : 10.1016/j.jacc.2021.09.1363
Volume 78, Issue 23, 7 December 2021, Page e297
Reply: Does Gestational Hypertension Contribute to Myocardial Fibrosis and Diastolic Dysfunction in Adult Offspring?
Adam J.LewandowskiDPhil
doi : 10.1016/j.jacc.2021.10.003
Volume 78, Issue 23, 7 December 2021, Page e299
